Madrigal Pharmaceuticals(MDGL) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Fourth quarter 2025 net sales reached $321.1 million, more than tripling from fourth quarter 2024, with full year 2025 net sales totaling $958.4 million [6][24] - The gross to net impact increased from the third quarter to the fourth quarter, with a full year average at the low end of the 20%-30% range previously outlined [24][25] - The company expects the gross to net impact for full year 2026 to be in the high 30% range, consistent with specialty medicine analogs [25][60] Business Line Data and Key Metrics Changes - The Rezdiffra launch solidified its position as the foundational therapy in MASH, with nearly $1 billion in net sales for its first full year on the market [4][6] - The number of patients on Rezdiffra increased to over 36,250 by the end of the fourth quarter, up from more than 29,500 at the end of the third quarter [9][10] - The US MASH market has grown nearly 50% since the end of 2023 and is expected to continue growing at a double-digit pace [4][10] Market Data and Key Metrics Changes - The F2, F3 target population of 315,000 patients seen by target specialists has expanded nearly 50% over the last two years [10] - The MASH market is expected to evolve similarly to other large specialty markets, potentially supporting 10-15+ therapies and exceeding $20 billion in annual sales [11] Company Strategy and Development Direction - The company aims to build a sustainable and durable franchise around Rezdiffra, leveraging its patent protection until 2045 and expanding its pipeline with complementary therapies [5][6] - The R&D strategy focuses on delivering outcomes data for Rezdiffra across various stages of MASH, advancing combination therapies, and utilizing non-invasive tests (NITs) for clinical assessments [15][45] - The company is pursuing a combination strategy that includes an oral GLP-1, a late-stage DGAT-2 inhibitor, and multiple siRNA targets, all designed to enhance the efficacy of Rezdiffra [18][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Rezdiffra and the MASH market, highlighting the strong fundamentals and the ability to steadily add patients [25][68] - The company anticipates robust net sales growth in 2026, despite expected increases in gross to net from contracting and typical first-quarter dynamics [25][60] Other Important Information - The company ended the fourth quarter of 2025 with $988.6 million in cash and equivalents, providing strong resources to support ongoing initiatives [28] - R&D expenses for the fourth quarter and full year 2025 were $116.3 million and $388.5 million, respectively, primarily due to business development activities [26] Q&A Session Summary Question: Can you elaborate on the drivers of meaningful growth in diagnosed patients and expectations for category growth in 2026? - Management noted strong growth driven by increased awareness and the presence of competitors like Novo, leading to more diagnoses and a clearer path to peak patient numbers [33][34] Question: What is the contribution of the Germany launch to worldwide revenues and patient numbers? - The contribution from Germany in 2025 was negligible, with expectations for minimal impact in 2026 as the focus remains on the US market [41][42] Question: How are you tracking blinded event rates for MAESTRO-NASH outcomes? - Management indicated that event rates are tracking as expected, with data delivery anticipated in 2027 [53] Question: What is the expected timing of MAESTRO-NASH outcomes now that the FDA has approved AI-supported pathology reads? - The MAESTRO Outcomes trial is event-driven and not histology-driven, so AI path reading will not be relevant for this study [84]